Press Releases

Year

September 5, 2024

4DMT Announces Presentations at Upcoming Retina Conferences

EMERYVILLE, Calif., Sept. 05, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced presentations at the

September 3, 2024

4DMT to Participate in the 2024 Cantor Global Healthcare Conference

EMERYVILLE, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced that management will

August 27, 2024

4DMT to Host 4D-150 Wet AMD Development Day on September 18, 2024

Company to highlight 4D-150 product development strategy and Phase 1/2 PRISM clinical trial data in wet age-related macular degeneration (wet AMD), including longest available interim follow-up data Overview of the 4FRONT Phase 3 clinical trial program in wet AMD Corporate webcast to be held on

August 12, 2024

4DMT to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

EMERYVILLE, Calif., Aug. 12, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced that management will

August 8, 2024

4DMT Reports Second Quarter 2024 Financial Results and Operational Highlights

Announced positive interim results from the Population Extension cohort of the Phase 2 PRISM clinical trial for 4D-150 in a broad wet age-related macular degeneration (wet AMD) population, which includes patients representative of the planned Phase 3 study population, affirming favorable safety

August 5, 2024

4DMT Advances Leadership in Large Market Ophthalmology with Senior Management Hires and Formation of Ophthalmology Advisory Board

Dhaval Desai, PharmD, named as Chief Development Officer; will oversee late-stage Product Development, Medical Affairs, Scientific Communications, Regulatory and Quality operations; most recently SVP & Chief Development Officer at Iveric Bio where he led development and approval of IZERVAY

July 17, 2024

4DMT Announces Positive Phase 2 PRISM Interim Results for Intravitreal 4D-150 in a Broad Wet AMD Population Affirming Favorable Safety Profile and Robust Clinical Activity

Robust reduction in anti-VEGF injection treatment burden through Week 24 achieved in 30 patients at planned Phase 3 dose (3E10 vg/eye) with 89% reduction in annualized injection rate; 93% of patients received 0 or 1 injection and 77% were injection-free Improvement in mean best corrected visual

June 24, 2024

4DMT Announces FDA Clearance of IND Application for 4D-175 Genetic Medicine for the Treatment of Geographic Atrophy

4D-175 comprises the proprietary low-dose intravitreal R100 AAV vector and a codon-optimized transgene encoding a highly functional shortened form of human complement factor H (sCFH) Complement factor H (CFH) variants with reduced function are a well-validated genetic risk factor for geographic

June 18, 2024

4DMT to Present Initial Interim 24-week Landmark Analysis from the 4D-150 Phase 2 PRISM Population Extension Cohort in a Broad Wet AMD Population at ASRS and Host a Corporate Webcast

24-week landmark safety and clinical activity data for 45 patients enrolled in the Population Extension cohort expected to be presented (N=30 at 3E10 vg/eye) Clinical data will be presented by Raj K. Maturi, M.D., a Principal Investigator in the PRISM study, at the American Society of Retina

June 8, 2024

4DMT Presents Injection-Free Subgroup Analyses from 4D-150 Phase 2 PRISM Randomized Dose Expansion Cohort in Wet AMD Patients with Severe Disease Activity & High Treatment Burden at the Clinical Trials at the Summit 2024 Meeting

Injection-free subgroup results demonstrated that a single intravitreal dose of 4D-150 without any supplemental anti-VEGF injections resulted in stable mean visual acuity that was equal to or higher than in the standard bimonthly aflibercept control group at all six timepoints through Week 24

Pagination

Current page 1
Page 2
Page 3
…
Next page
Last page

About 4DMT

Navigation

Location